Summary:
- Quest Diagnostics (DGX, Financial) beats first-quarter earnings estimates with a notable revenue increase.
- Analysts project an average price target of $180.78, indicating a potential 11.69% upside.
- The company's average brokerage recommendation suggests an "Outperform" status.
Quest Diagnostics (DGX) recently announced its financial results for the first quarter. The company reported non-GAAP earnings per share of $2.21, which surpassed market expectations by $0.06. Revenue for the quarter stood at $2.65 billion, marking a 12.1% increase compared to the same period last year, and beating forecasts by $20 million. For the full-year 2025 guidance, Quest Diagnostics anticipates revenues ranging between $10.70 billion and $10.85 billion.
Wall Street Analysts Forecast
In evaluating the future outlook for Quest Diagnostics Inc (DGX, Financial), 16 analysts have provided one-year price targets. The average target price is set at $180.78, with the highest estimate at $198.00 and the lowest at $160.00. This average target suggests an upside potential of 11.69% from the current stock price of $161.86. Additional details and estimates are available on the Quest Diagnostics Inc (DGX) Forecast page.
The consensus recommendation from 20 brokerage firms places Quest Diagnostics Inc (DGX, Financial) at an average brokerage recommendation of 2.2. This rating reflects an "Outperform" status, based on a scale where 1 indicates a Strong Buy and 5 denotes a Sell.
Valuation Insights
GuruFocus provides an estimated GF Value for Quest Diagnostics Inc (DGX, Financial) of $156.78 for the next year. This figure implies a potential downside of 3.14% from the current price of $161.86. The GF Value is determined by analyzing the stock's historical trading multiples, previous business growth, and projected future performance. For more comprehensive data, visit the Quest Diagnostics Inc (DGX) Summary page.
